Pacira BioSciences (NASDAQ:PCRX – Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.70 earnings per share for the quarter, missing the consensus estimate of $0.73 by ($0.03), FiscalAI reports. The business had revenue of $176.65 million during the quarter, compared to the consensus estimate of $182.87 million. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%.
Pacira BioSciences Stock Performance
Shares of PCRX traded up $0.01 on Friday, reaching $36.43. 537,093 shares of the stock traded hands, compared to its average volume of 2,693,118. The stock’s 50-day moving average price is $30.17 and its 200-day moving average price is $25.21. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.04 and a quick ratio of 3.94. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of 104.09 and a beta of 0.21. Pacira BioSciences has a 12 month low of $18.80 and a 12 month high of $36.67.
Wall Street Analyst Weigh In
A number of analysts have weighed in on PCRX shares. Royal Bank Of Canada increased their price target on shares of Pacira BioSciences from $25.00 to $36.50 and gave the company a “sector perform” rating in a report on Friday, October 9th. HC Wainwright downgraded shares of Pacira BioSciences from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $38.00 to $36.50 in a report on Friday, October 9th. Jefferies Financial Group lowered shares of Pacira BioSciences from a “buy” rating to a “hold” rating and set a $36.00 price objective for the company. in a research report on Thursday, October 8th. Weiss Ratings raised shares of Pacira BioSciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, October 8th. Finally, Needham & Company LLC cut shares of Pacira BioSciences from a “buy” rating to a “hold” rating in a research note on Thursday, October 8th. One analyst has rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, Pacira BioSciences has a consensus rating of “Hold” and a consensus price target of $33.33.
Read Our Latest Report on PCRX
Insider Buying and Selling at Pacira BioSciences
In related news, SVP Lauren Riker sold 6,000 shares of the firm’s stock in a transaction on Thursday, October 8th. The stock was sold at an average price of $36.32, for a total value of $217,920.00. Following the completion of the transaction, the senior vice president directly owned 62,284 shares of the company’s stock, valued at $2,262,154.88. This trade represents a 8.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jonathan Slonin sold 3,040 shares of Pacira BioSciences stock in a transaction on Monday, August 17th. The stock was sold at an average price of $23.23, for a total transaction of $70,619.20. Following the sale, the insider owned 216,384 shares in the company, valued at $5,026,600.32. This represents a 1.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is owned by company insiders.
Pacira BioSciences Company Profile
Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management and regenerative health solutions. The company’s products are designed to address acute postsurgical pain and osteoarthritis-related pain while supporting efforts to reduce reliance on opioid medications.
Pacira’s lead product is EXPAREL, an extended-release formulation of bupivacaine administered by injection for postsurgical pain management. The company also markets ZILRETTA, an extended-release corticosteroid injection indicated for osteoarthritis knee pain, and iovera°, a cryoanalgesia system that uses controlled cooling to temporarily block peripheral nerves and relieve pain.
Formerly known as Pacira Pharmaceuticals, the company adopted the Pacira BioSciences name to reflect its broader focus on innovative pain and regenerative-health therapies.
Featured Stories
- Five stocks we like better than Pacira BioSciences
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
